ArticleJAMA network open2025
Early Postpartum Glucose Tolerance Reclassification by Gestational Diabetes Subtype.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipidomic signatures in gestational diabetes mellitus and postpartum type 2 diabetes mellitus: a narrative review of etiologic and predictive implications.EBioMedicine · 2026Review
- Rethinking the Postpartum "Orphan Window" Treatment in Gestational Diabetes Management.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Importance: Gestational diabetes (GD) is a heterogeneous condition that predisposes both mother and offspring to metabolic disorders. GD subtypes defined by antepartum testing results have been associated with adverse perinatal outcomes, but little is known about their relationship to maternal metabolic outcomes soon after pregnancy. Objective: To evaluate early postpartum glucose tolerance reclassification of GD subtypes. Design, Setting, and Participants: This cohort study examined women from the Study of Women, Infant Feeding, and Type 2 Diabetes Mellitus After GD Pregnancy (SWIFT), who were recruited within the Kaiser Permanente Northern California integrated health care system between 2008 and 2011. All women were diagnosed with GD using Carpenter and Coustan criteria with complete glucose measurements at all 4 time points of the diagnostic 3-hour 100-gram oral glucose tolerance test (OGTT). Data analyses were conducted from January to July 2025. Exposure: Three subtypes of GD based on the diagnostic OGTT: (1) postload glucose intolerance (GD-P), as having elevations only at 2 or more postload time points; (2) fasting hyperglycemia (GD-F), as having elevations at fasting and 1 postload time point; and (3) both (GD-M), as having elevations at fasting and 2 or more post-load time points. Main Outcomes and Measures: At 6 to 9 weeks after delivery, glucose tolerance classification was evaluated using 2-hour, 75-g OGTTs. Modified Poisson regression models were used to estimate adjusted prevalence ratios (PRs) of postpartum prediabetes associated with GD subtypes, without and with adjustments for age, race and ethnicity, prepregnancy body mass index, educational level, and gestational weight gain. Results: This study included 1005 women with GD (median [IQR] age, 33.2 [29.8-36.7] years; 368 [36.6%] Asian, 78 [7.8%] Black, 308 [30.6%] Hispanic, 16 [1.6%] multiracial, and 235 [23.4%] White). Prevalence of postpartum prediabetes was 34.5% (347 women), with wide variation across GD subtypes; 23.9% (147 of 616), 41.9% (52 of 124), and 55.8% (148 of 265) for GD-P, GD-F, and GD-M, respectively. Compared with women with GD-P, the adjusted PR for GD-F was 1.74 (95% CI, 1.36-2.24), and for GD-M, it was 2.23 (95% CI, 1.85-2.68) (both P < .001). Pairwise comparisons between GD-F and GD-M were also statistically significant (adjusted PR, 1.28; 95% CI, 1.01-1.61; P = .04). Conclusions and Relevance: In this cohort study, GD subtypes had distinct postpartum prediabetes risks. Early action and intervention to address dysglycemia may be most beneficial for women with fasting or mixed defects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.